These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 29637859)
1. Melatonin Treatment Enhances Aβ Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis. Pappolla MA; Matsubara E; Vidal R; Pacheco-Quinto J; Poeggeler B; Zagorski M; Sambamurti K Curr Alzheimer Res; 2018; 15(7):637-642. PubMed ID: 29637859 [TBL] [Abstract][Full Text] [Related]
2. Evidence for lymphatic Aβ clearance in Alzheimer's transgenic mice. Pappolla M; Sambamurti K; Vidal R; Pacheco-Quinto J; Poeggeler B; Matsubara E Neurobiol Dis; 2014 Nov; 71():215-9. PubMed ID: 25102344 [TBL] [Abstract][Full Text] [Related]
3. Long-term oral melatonin alleviates memory deficits, reduces amyloid-β deposition associated with downregulation of BACE1 and mitophagy in APP/PS1 transgenic mice. Sun C; Qiu X; Wang Y; Liu J; Li Q; Jiang H; Li S; Song C Neurosci Lett; 2020 Sep; 735():135192. PubMed ID: 32619650 [TBL] [Abstract][Full Text] [Related]
4. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis. Liao F; Hori Y; Hudry E; Bauer AQ; Jiang H; Mahan TE; Lefton KB; Zhang TJ; Dearborn JT; Kim J; Culver JP; Betensky R; Wozniak DF; Hyman BT; Holtzman DM J Neurosci; 2014 May; 34(21):7281-92. PubMed ID: 24849360 [TBL] [Abstract][Full Text] [Related]
5. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease. Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding. Shackleton B; Crawford F; Bachmeier C Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326 [TBL] [Abstract][Full Text] [Related]
7. Amyloid binding ligands as Alzheimer's disease therapies. Lee VM Neurobiol Aging; 2002; 23(6):1039-42. PubMed ID: 12470800 [TBL] [Abstract][Full Text] [Related]
8. Aβ seeding potency peaks in the early stages of cerebral β-amyloidosis. Ye L; Rasmussen J; Kaeser SA; Marzesco AM; Obermüller U; Mahler J; Schelle J; Odenthal J; Krüger C; Fritschi SK; Walker LC; Staufenbiel M; Baumann F; Jucker M EMBO Rep; 2017 Sep; 18(9):1536-1544. PubMed ID: 28701326 [TBL] [Abstract][Full Text] [Related]
9. Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice. Wang L; Zhang Y; Zhao Y; Marshall C; Wu T; Xiao M Brain Pathol; 2019 Mar; 29(2):176-192. PubMed ID: 30192999 [TBL] [Abstract][Full Text] [Related]
10. Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer's disease. Li Y; Zhang J; Wan J; Liu A; Sun J Biomed Pharmacother; 2020 Dec; 132():110887. PubMed ID: 33254429 [TBL] [Abstract][Full Text] [Related]
11. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease. Kuznetsova E; Schliebs R Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514 [TBL] [Abstract][Full Text] [Related]
12. Increased soluble amyloid-beta causes early aberrant brain network hypersynchronisation in a mature-onset mouse model of amyloidosis. Ben-Nejma IRH; Keliris AJ; Daans J; Ponsaerts P; Verhoye M; Van der Linden A; Keliris GA Acta Neuropathol Commun; 2019 Nov; 7(1):180. PubMed ID: 31727182 [TBL] [Abstract][Full Text] [Related]
13. Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Izco M; Martínez P; Corrales A; Fandos N; García S; Insua D; Montañes M; Pérez-Grijalba V; Rueda N; Vidal V; Martínez-Cué C; Pesini P; Sarasa M Neuroscience; 2014 Mar; 263():269-79. PubMed ID: 24447596 [TBL] [Abstract][Full Text] [Related]
14. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Qosa H; Abuasal BS; Romero IA; Weksler B; Couraud PO; Keller JN; Kaddoumi A Neuropharmacology; 2014 Apr; 79():668-78. PubMed ID: 24467845 [TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Castellano JM; Deane R; Gottesdiener AJ; Verghese PB; Stewart FR; West T; Paoletti AC; Kasper TR; DeMattos RB; Zlokovic BV; Holtzman DM Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15502-7. PubMed ID: 22927427 [TBL] [Abstract][Full Text] [Related]
16. Knockout of apolipoprotein A-I decreases parenchymal and vascular β-amyloid pathology in the Tg2576 mouse model of Alzheimer's disease. Contu L; Carare RO; Hawkes CA Neuropathol Appl Neurobiol; 2019 Dec; 45(7):698-714. PubMed ID: 31002190 [TBL] [Abstract][Full Text] [Related]
17. Ultrasound-mediated augmented exosome release from astrocytes alleviates amyloid-β-induced neurotoxicity. Deng Z; Wang J; Xiao Y; Li F; Niu L; Liu X; Meng L; Zheng H Theranostics; 2021; 11(9):4351-4362. PubMed ID: 33754065 [No Abstract] [Full Text] [Related]
18. Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis. Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM BMC Neurosci; 2018 Jul; 19(1):46. PubMed ID: 30055565 [TBL] [Abstract][Full Text] [Related]
19. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Kawarabayashi T; Younkin LH; Saido TC; Shoji M; Ashe KH; Younkin SG J Neurosci; 2001 Jan; 21(2):372-81. PubMed ID: 11160418 [TBL] [Abstract][Full Text] [Related]
20. Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model. Qosa H; Batarseh YS; Mohyeldin MM; El Sayed KA; Keller JN; Kaddoumi A ACS Chem Neurosci; 2015 Nov; 6(11):1849-59. PubMed ID: 26348065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]